Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Richter transformation (RT) of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma has an estimated median OS of only 8-12 mo. Tisagenlecleucel CAR-T cell therapy is approved for treatment of r/r LBCL after ≥2 lines of prior therapy. Here, we describe the efficacy and safety of tisagenlecleucel in patients (pts) with RT in a real-world setting with a median follow-up (infusion to data cutoff) of 31 mo.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Mazyar Shadman, Matthew J. Frigault, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron A. Jacobson, Samantha Jaglowski, Frederick L. Locke, Daniel J. Landsburg, Ron Ram, Peter A. Riedell, Gunjan L. Shah, Leslie Popplewell, Ranjan Tiwari, Stephen Tags: 245 Source Type: research